Survival RateSurvival AnalysisTreatment OutcomePrognosisDisease-Free SurvivalCell SurvivalRetrospective StudiesNeoplasm StagingFollow-Up StudiesKaplan-Meier EstimateCombined Modality TherapyTime FactorsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalLung NeoplasmsSurvivalGraft SurvivalProportional Hazards ModelsLiver NeoplasmsAdenocarcinomaCisplatinLymphatic MetastasisMultivariate AnalysisActuarial AnalysisHepatectomyCarcinoma, Non-Small-Cell LungStomach NeoplasmsCarcinoma, Squamous CellChemotherapy, AdjuvantGastrectomyCarcinoma, HepatocellularPancreatic NeoplasmsLymph Node ExcisionEsophageal NeoplasmsRisk FactorsRadiotherapy, AdjuvantNeoplasm MetastasisPostoperative ComplicationsProspective StudiesLiver TransplantationTumor Markers, BiologicalAntineoplastic AgentsBile Duct NeoplasmsFluorouracilAge FactorsDrug Administration ScheduleRegistriesNeoplasm InvasivenessReoperationRadiotherapy DosageVincristineRemission InductionImmunohistochemistryRecurrenceCohort StudiesCarcinomaCholangiocarcinomaDisease ProgressionDoxorubicinRisk AssessmentDeoxycytidineEsophagectomyColorectal NeoplasmsCyclophosphamidePneumonectomyBreast NeoplasmsRectal NeoplasmsChemoembolization, TherapeuticEtoposideMetastasectomyCarboplatinNeoadjuvant TherapyLife TablesBile Ducts, IntrahepaticPancreatectomyVinblastinePaclitaxelCarcinoma, Small CellBrain NeoplasmsRadiotherapy, High-EnergyPredictive Value of TestsPatient SelectionJapanSarcomaAntimetabolites, AntineoplasticChi-Square DistributionApoptosisTegafurDose FractionationIncidenceSalvage TherapyBone NeoplasmsPalliative CareChemoradiotherapyRadiotherapySEER ProgramCell Line, TumorGallbladder NeoplasmsMelanomaPrednisone